2Q Pharma Results Preview: Bristol, AstraZeneca, Roche, Celgene, Bayer, Merck, AbbVie & Sanofi
Executive Summary
PD-1 inhibitor performance and the intense curiosity around AstraZeneca both for its MYSTIC trial and Soriot's faithfulness to the company are key themes at the half-year mark. Eyes are also on commercial performance for Roche's Ocrevus and Merck's anacetrapib for clarity on whether it has a commercial future.
You may also be interested in...
Celgene Eases Angst Over Otezla, Sets The Stage For Growth
Celgene reported second quarter sales growth for key assets in its commercial portfolio, including a recovery for Otezla, and prepared investors for a deluge of data in the second half of 2017.
Cancer Drugs Boost Bayer Despite Crop, Consumer and Currency Concerns
The still pending acquisition of Monsanto, crop science problems in Brazil and a weak showing from consumer health in the US cannot disguise the strong growth that Bayer's pharmaceuticals business is continuing to enjoy.
Merck's Keytruda Gets Benefit Of Doubt, Despite Failing in Head & Neck
Prior PD-1 failures after accelerated approval include Roche's Tecentriq in bladder cancer.